Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

64 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Relapsed/Refractory International Prognostic Index (R/R-IPI): An international prognostic calculator for relapsed/refractory diffuse large B-cell lymphoma.
Maurer MJ, Jakobsen LH, Mwangi R, Schmitz N, Farooq U, Flowers CR, de Nully Brown P, Thompson CA, Frederiksen H, Cunningham D, Jørgensen J, Poeschel V, Nowakowski G, Seymour JF, Merli F, Haioun C, Ghesquieres H, Ziepert M, Tilly H, Salles G, Shi Q, El-Galaly TC, Habermann TM. Maurer MJ, et al. Among authors: mwangi r. Am J Hematol. 2021 May 1;96(5):599-605. doi: 10.1002/ajh.26149. Epub 2021 Mar 18. Am J Hematol. 2021. PMID: 33661547 Free PMC article.
Patterns of therapy initiation during the first decade for patients with follicular lymphoma who were observed at diagnosis in the rituximab era.
Arushi Khurana, Mwangi R, Ansell SM, Habermann TM, Cerhan JR, Strouse C, Link BK, Wang Y, King RL, Macon WR, Villasboas JC, Witzig TE, Maurer MJ, Nowakowski GS. Arushi Khurana, et al. Among authors: mwangi r. Blood Cancer J. 2021 Jul 17;11(7):133. doi: 10.1038/s41408-021-00525-0. Blood Cancer J. 2021. PMID: 34274939 Free PMC article.
Clinicopathologic Characteristics, Treatment, and Outcomes of Post-transplant Lymphoproliferative Disorders: A Single-institution Experience Using 2017 WHO Diagnostic Criteria.
King RL, Khurana A, Mwangi R, Fama A, Ristow KM, Maurer MJ, Macon WR, Ansell SM, Bennani NN, Kudva YC, Walker RC, Watt KD, Schwab TR, Kushwaha SS, Cerhan JR, Habermann TM. King RL, et al. Among authors: mwangi r. Hemasphere. 2021 Sep 6;5(10):e640. doi: 10.1097/HS9.0000000000000640. eCollection 2021 Oct. Hemasphere. 2021. PMID: 34514344 Free PMC article.
Vaccination History and Risk of Lymphoma and Its Major Subtypes.
Kleinstern G, Larson MC, Ansell SM, Thompson CA, Nowakowski GS, Call TG, Robinson DP, Maurer MJ, Mwangi R, Feldman AL, Kay NE, Novak AJ, Habermann TM, Slager SL, Cerhan JR. Kleinstern G, et al. Among authors: mwangi r. Cancer Epidemiol Biomarkers Prev. 2022 Feb;31(2):461-470. doi: 10.1158/1055-9965.EPI-21-0383. Epub 2021 Nov 15. Cancer Epidemiol Biomarkers Prev. 2022. PMID: 34782394 Free PMC article.
PET2 response associated with survival in newly diagnosed diffuse large B-cell lymphoma: results of two independent prospective cohorts.
Desai SH, Pederson L, LaPlant B, Mwangi R, Maurer M, Young JR, Macon WR, King RL, Wang Y, Cerhan JR, Feldman A, Inwards DJ, Micallef I, Johnston P, Porrata LF, Ansell SM, Habermann TM, Witzig TE, Nowakowski GS. Desai SH, et al. Among authors: mwangi r. Blood Cancer J. 2022 May 3;12(5):78. doi: 10.1038/s41408-022-00649-x. Blood Cancer J. 2022. PMID: 35504884 Free PMC article.
Causes of death in low-grade B-cell lymphomas in the rituximab era: a prospective cohort study.
Tun AM, Khurana A, Mwangi R, Link BK, Wang Y, Feldman AL, Thompson CA, Novak AJ, Villasboas JC, Thanarajasingam G, Farooq U, Syrbu S, Nowakowski GS, Witzig TE, Ansell SM, Rimsza LM, Cerhan JR, Habermann TM, Maurer MJ. Tun AM, et al. Among authors: mwangi r. Blood Adv. 2022 Sep 13;6(17):5210-5221. doi: 10.1182/bloodadvances.2022007990. Blood Adv. 2022. PMID: 35849723 Free PMC article.
64 results